Prospective study of radiation related adverse events and its management in cancer patient at tertiary care teaching hospital

Authors

  • Rohit . Department of Pharmacy Practice, Indo Soviet Friendship College of Pharmacy, Moga, Punjab, India
  • Devesh Kumar Joshi Department of Pharmacy Practice, Shri Guru Ram Rai Institute of Technology and Science, Dehradun, Uttarakhand, India
  • Raja Paramjeet Singh Banipal Department of Oncology, Guru Gobind Singh Medical College and Hospital, Faridkot, Punjab, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20180658

Keywords:

Adverse events, Chemo-radiation effects, Management, RTOG, Radiotherapy

Abstract

Background: Radiation therapy is associated with certain adverse events which may cause significant discomfort to patient and may affect patient’s life. The objective of the study was to assess radiation related adverse events in the patients who are on radiation therapy and to prevent and manage these adverse events.

Methods: A prospective observational study was conducted on 193 patients receiving radiotherapy in Oncology Department at Guru Gobind Singh Medical College and Hospital, Faridkot, Punjab. One fraction (2 Gray) dose had been given to patients daily for five days in a week and monitor. The collected data was analyzed by applying IBM SPSS v21.

Results: The clinical results observed in 193 consecutive patients with follow-up of 7 weeks and graded according to RTOG Acute Radiation Morbidity Scoring Criteria. Majority of events were reported in age group of 41-60 years followed by 61-80 years, 20-40 years. Epidermal, mucosal, Genitourinary and Lower G.I. reactions are graded. The reactions managed by providing symptomatic treatment.

Conclusions: Radiation related adverse events have been found frequently in patients with radiotherapy and chemo-radiotherapy both. As the number of doses increase with time the grade of reactions also increases. Appropriate follow-up and management of these events reduces patient burden of treatment.

References

NIH. What Is Cancer?: National Cancer Institute; 2016 [updated 9 February 2015; cited 2016 25 February]. Available at: http://www.cancer.gov/about-cancer/what-is-cancer.

WHO. All Cancers (excluding non-melanoma skin cancer) Estimated Incidence, Mortality and Prevalence Worldwide in 2012: GLOBOCAN 2012: International Agency for Research on Cancer; 2016 [cited 2016,25 February]. Available at: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx.

American cancer society. A Guide to Radiation therapy American Cancer Society; 2015 [cited 2015, 22-September]. Available at: http://www.cancer.org/acs /groups/cid/documents/webcontent/003028-pdf.

Powlis WD, Altschuler MD, Censor Y, Buhle EL. Semi-automated radiotherapy treatment planning with a mathematical model to satisfy treatment goals. International Journal of Radiation Oncology Biology Physics. 1989;16(1):271-6.

Zelefsky MJ, Chan H, Hunt M, Yamada Y, Shippy AM, Amols H. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. The Journal of urology. 2006;176(4):1415-9.

Allen AM, Czerminska M, Jänne PA, Sugarbaker DJ, Bueno R, Harris JR, et al. Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. International Journal of Radiation Oncology Biology Physics. 2006;65(3):640-5.

Whitney CW, Sause W, Bundy BN, Malfetano JH, Hannigan EV, Fowler Jr WC, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. Journal of Clinical Oncology. 1999;17(5):1339.

US Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) version 4.0. National Institutes of Health, National Cancer Institute. 2009;4(03).

NIH. NCI Dictionary of Cancer Terms: National cancer institute; 2016 [updated 9 February 2015; cited 2016, 5-April]. Available at: http://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=444960.

Cox JD, Stetz J, Pajak TF. Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC). International Journal of Radiation Oncology Biology Physics. 1995;31(5):1341-6.

U.K. (2013, 10 July 2015). Cancer Registration Statistics, England: 2013. Retrieved 26-April, 2016. Available at: http://www.ons.gov.uk/peoplepopulation andcommunity/healthandsocialcare/conditionsanddiseases/bulletins/cancerregistrationstatisticsengland/2015-07-10.

Singla S, Naik V, Kini R, Shetty A. Cumulative dose related adverse effects of radiation therapy on oral cavity. International Journal of Medical and Applied Sciences. 2014;3(2):106-10.

Homma A, Inamura N, Oridate N, Suzuki S, Hatakeyama H, Yasuda MT. Concomitant weekly cisplatin and radiotherapy for head and neck cancer. Japanese Journal of Clinical Oncology. 2011;41(8):980-6.

Vicini FA, Sharpe M, Kestin L, Martinez A, Mitchell CK, Wallace M, et al. Optimizing breast cancer treatment efficacy with intensity-modulated radiotherapy. International Journal of Radiation Oncology Biology Physics. 2002;54(5):1336-44.

Downloads

Published

2018-02-22

How to Cite

., R., Joshi, D. K., & Banipal, R. P. S. (2018). Prospective study of radiation related adverse events and its management in cancer patient at tertiary care teaching hospital. International Journal of Basic & Clinical Pharmacology, 7(3), 451–456. https://doi.org/10.18203/2319-2003.ijbcp20180658

Issue

Section

Original Research Articles